Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VistaGen Therapeutics and University Health Network Extend Collaborative Stem Cell Research

Published: Thursday, November 17, 2011
Last Updated: Thursday, November 17, 2011
Bookmark and Share
Alliance Supports Drug Rescue Initiatives, Cell Therapy Applications, and Focus on Large-Scale Production of Stem Cells

Therapeutics, Inc. a biotechnology company applying stem cell technology for drug rescue and cell therapy, and the University Health Network (UHN), one of Canada's largest research hospitals, have expanded their existing collaborative pluripotent stem cell research and development program, and extended it through September 2017.

In 2007, VistaGen and Dr. Gordon Keller, head of UHN's McEwen Centre for Regenerative Medicine in Toronto, agreed to combine Dr. Keller's human pluripotent stem cell biology expertise with VistaGen's proprietary Human Clinical Trials in a Test Tube™ stem cell technology platform. The platform delivers clinically relevant indications of how humans will respond to new drug candidates early in the drug development process. Dr. Ralph Snodgrass, VistaGen's President and Chief Scientific Officer, and Dr. Keller, who is chairman of VistaGen's Scientific Advisory Board, co-founded VistaGen in 1998, with the goal of using stem cell technologies to transform the way new drugs are discovered and developed.

"Our unique relationship with UHN and Dr. Keller is dynamic, innovative and directly supports the drug rescue capabilities of our Human Clinical Trials in a Test Tube™ platform," said Shawn Singh, VistaGen's Chief Executive Officer. "This research partnership gives us direct access to cutting-edge stem cell research conducted by one of the world's leading stem cell researchers at one of the world's top stem cell research institutions."
Dr. Christopher Paige, UHN's Vice President, Research, said, "We are very pleased with the progress Dr. Keller's lab and VistaGen are making in our cooperative research effort. VistaGen's support of Dr. Keller and his team, and its commitment to commercializing these technologies, give us confidence that we will soon see the remarkable promise of our collaborative stem cell research translated into therapeutic realities that will improve patients' lives."

The amended UHN agreement includes five key programs that will further support VistaGen's core drug rescue initiatives and potential cell therapy applications.

Research conducted at UHN and VistaGen labs will include the development of stem cell-based drug discovery and drug rescue technologies, using mature cardiac, liver and pancreatic beta-islet, blood and cartilage cells. The program will also focus on large-scale production of these cell types, each derived from human-induced pluripotent stem cells (hiPS cells), which are potentially suitable for in vivo transplantation studies and cell therapy applications.

Additionally, VistaGen and UHN scientists plan to further enhance current methods used to produce cell types derived from both human embryonic stem cells (hES cells) and hiPS cells. The research alliance also aims to establish preclinical proof-of-concept for the use of iPS cell-derived articular chondrocytes for cell therapy repair and regeneration of autologous cartilage, as well as the use of iPS cell-derived precursor cells to produce lymphocytes, granulocytic cells, red cells and blood platelets.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VistaGen Secures Key U.S. Stem Cell Technology Patent
United States patent covers the company's proprietary methods used to measure and type the toxic effects produced by drug compounds in liver stem cells.
Thursday, April 26, 2012
VistaGen Increases Its Drug Rescue Opportunities
Long-term relationship with global contract research and development organization expands to include right-of-first-offer for potential drug rescue candidates.
Thursday, February 09, 2012
VistaGen Therapeutics Reports Advances in its Pancreatic Cell and Regenerative Medicine Programs
Use of pluripotent stem cells to generate insulin in mice.
Tuesday, September 27, 2011
VistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives
VistaGen provides comprehensive update on the Company's strategic plan to develop and commercialize its technology platform and lead small molecule CNS drug candidate.
Friday, September 16, 2011
Vistagen Therapeutics Announces Publications Supporting the Use of Embryonic Stem Cells
The publications highlight advances to understand how embryonic stem cells can be reproducibly differentiated into heart and liver cells.
Thursday, December 28, 2006
Scientific News
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
1960s Antibiotics Show Promise for TB Therapy
Research suggests antibiotics introduced in 1963 to treat bacterial infections show promise for tuberculosis therapy.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Studies Explore the Science of Cardiovascular Diseases
Two studies highlight how basic science research insights are key to future treatment breakthroughs.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Stem Cell Transplant Without Radiation or Chemotherapy
Researchers have successfully performed stem cell transplants without using radiation or chemotherapy.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!